It is not clear whether this phenomenon was due to the higher dose used during challenge or to the intranodal route of selleck chemical inoculation or that BCG Tokyo for challenge was derived from frozen logarithmic growth phase liquid stocks, whilst for vaccination lyophilised BCG SSI was resuspended in Sauton’s medium. Intranodal inoculation has been reported to be more immunogenic than the intradermal or intravenous routes of immunisation [16] and [17]

and it is possible that this route of inoculation may induce stronger immune responses than those normally induced by BCG which may translate into greater protection against M. bovis. Future experiments will be necessary to test this hypothesis. Whilst it was not the purpose of this study to establish the extent of dissemination of BCG in cattle, these experiments provide evidence that BCG spreads to organs other than those directly inoculated. However, it is important to state that these results cannot be correlated to what would happen following subcutaneous vaccination due to the following reasons: the strain used for challenge was BCG Tokyo from

frozen mid-log liquid cultures whilst BCG SSI, the strain used for vaccination, is genetically different and was used as a lyophilised suspension. The dose used for vaccination was 100 fold lower than the dose used for challenge and the vaccine was administered s.c. whilst the challenge was given intranodally. It is also worth pointing out that, after challenge, BCG Tokyo was more widely distributed in non-vaccinated cattle than in vaccinated cattle. The bacteria

obtained from lymph nodes Dasatinib price other than the right prescapular lymph node, the site of injection, were confirmed by genetic typing to be BCG Tokyo and not BCG SSI (results not shown). Thus, we did not detect BCG SSI in the lymph nodes examined in these experiments at 10 (week 2 after challenge) and 11 (week 3 after challenge) weeks after s.c. inoculation. In conclusion, this target species model Isotretinoin can be used as a gating system for vaccine candidates prior to further testing in BSL 3 facilities using virulent M. bovis challenge. This model could also be used to further explore the bovine primary and secondary elements of an immune response against mycobacteria in order to determine which factors are important in the control and/or killing of mycobacteria. This work was supported by funding from the Department for International Development, U.K. and the Bill and Melinda Gates Foundation. HMcS, RGH and HMV are Jenner Investigators. None. The authors are grateful to members of the Animal Services Unit for their exemplary care of all animals used in these experiments. The authors also wish to acknowledge the contribution of Mr. Julian Cook, Dr Ute Weyer and Dr. Timm Konold in the shooting, presentation and editing of the supplemental video showing the intranodal inoculation technique.